Asin K E, Bednarz L, Nikkel A, Perner R
Abbott Laboratories, Neuroscience Research Division, Department 47U, Abbott Park, Illinois, USA.
J Pharmacol Exp Ther. 1995 Jun;273(3):1483-90.
The available evidence suggests that daily injections of selective dopamine (DA) D2 receptor agonists to DA depleted rats typically leads to behavioral sensitization, but the effects of repeated treatment with selective DA D1 receptor agonists are more equivocal. In this study we examined the effects of acute and repeated treatment with DA receptor agonists with various D1/D2 receptor selectivities on rotation and striatal c-fos activation in rats with unilateral DA depletions. Lesioned rats were treated daily for 10 d with either the novel, selective DA D1 receptor agonist, A-85653, the DA D2 receptor agonist, quinpirole, a combination of these compounds, or the indirect D1/D2 receptor agonist levodopa (L-DOPA). Over days, rats given A-85653 alone showed behavioral tolerance, whereas those given either quinpirole or L-DOPA demonstrated behavioral sensitization. Repeated A-85653 + quinpirole treatment s lead to an increase in response magnitude early in the testing sessions and this was accompanied by a reduction in response duration over days. Quantitative analysis of striatal c-fos activation was also conducted in lesioned rats treated acutely or repeatedly with A-85653, A-85653 + quinpirole or L-DOPA. Numbers of Fos-immunoreactive nuclei were sharply reduced after the agonist challenge in all animals given repeated, compared to acute, drug treatment, despite enhanced levels of rotation by rats given quinpirole + A-85653 or L-DOPA repeatedly. These results suggest that desensitization may develop at the DA D1 receptor as a consequence of repeated stimulation, and that the behavioral sensitization seen after repeated L-DOPA treatment may primarily involve the DA D2 receptor.
现有证据表明,每日给多巴胺(DA)耗竭的大鼠注射选择性DA D2受体激动剂通常会导致行为敏化,但选择性DA D1受体激动剂反复治疗的效果则更具不确定性。在本研究中,我们研究了用具有不同D1/D2受体选择性的DA受体激动剂对单侧DA耗竭大鼠进行急性和反复治疗对其旋转行为及纹状体c-fos激活的影响。对损伤大鼠每日进行为期10天的治疗,分别给予新型选择性DA D1受体激动剂A-85653、DA D2受体激动剂喹吡罗、这两种化合物的组合或间接D1/D2受体激动剂左旋多巴(L-DOPA)。随着时间推移,单独给予A-85653的大鼠表现出行为耐受,而给予喹吡罗或L-DOPA的大鼠则表现出行为敏化。反复给予A-85653 +喹吡罗治疗会使测试初期反应幅度增加,且随着时间推移反应持续时间缩短。我们还对急性或反复给予A-85653、A-85653 +喹吡罗或L-DOPA治疗的损伤大鼠的纹状体c-fos激活进行了定量分析。与急性药物治疗相比,在所有反复接受药物治疗的动物中,激动剂激发后Fos免疫反应性细胞核数量急剧减少,尽管反复给予喹吡罗+ A-85653或L-DOPA的大鼠旋转水平增强。这些结果表明,反复刺激可能导致DA D1受体脱敏,且反复给予L-DOPA治疗后出现的行为敏化可能主要涉及DA D2受体。